Scientific Advisory Board

Scientific Advisory Board

George Siber, M.D., Ph.D., Chair
Chief Scientific Officer, ClearPath Vaccines Company
Former Chief Scientific Officer, Wyeth Vaccines
Adjunct Professor of Medicine at Johns Hopkins Medical School

Dr. Siber is an internationally recognized vaccine expert with decades of experience in developing innovative vaccines. Dr. Siber’s prior professional experiences include Executive Vice President and Chief Scientific Officer of Wyeth Vaccines Research, overseeing the development, approval and marketing of six innovative childhood vaccines including Prevenar 7, the first pneumococcal conjugate vaccine, Meningitec, the first Meningococcal C conjugate vaccine, Rotashield, the first rotavirus vaccine and FluMist, the first live nasal influenza vaccine. Prevenar 7 has dramatically reduced the burden of pneumococcal disease in the countries that have introduced it and has become the largest selling vaccine (more than $4 Billion per year).  Previous to Wyeth, Dr. Siber served as Associate Professor of Medicine at Harvard Medical School and Director of the Massachusetts Biologic Laboratories. Under his leadership, the specific immune globulins to CMV (Cytogam) and to RSV (Respigam) the precursor product to Synagis were developed and licensed to MedImmune. Currently, Dr. Siber is Chief Scientific Officer of ClearPath Vaccines Company, a vaccine development company focused on developing novel vaccines with high medical need to create a global vaccine portfolio for Astellas Pharma. Dr. Siber is the 2016 recipient of the Albert B. Sabin Gold Medal awarded for pioneering in vaccines. Dr. Siber received his undergraduate degree at Bishop’s University in Lennoxville, Quebec and his medical degree from McGill University in Montreal.

Chuck Drake, M.D., Ph.D.
Director of Genitourinary Oncology, New York-Presbyterian/Columbia University Medical Center
Associate Director for Clinical Research at the Herbert Irving Comprehensive Cancer Center
Co-director of Cancer Immunotherapy Programs at Columbia University Medical Center

One of the influential leaders in immunotherapy and in prostate cancer research and therapies, Dr. Drake is a physician-scientist known for rapidly incorporating discoveries made in the research lab into innovative clinical trials, including anti-tumor vaccines and immunotherapies. Previously, Dr. Drake served as the co-director of the Cancer Immunology Program at Johns Hopkins School of Medicine and as co-director of the Prostate Cancer Multi-Disciplinary Clinic. Earlier in his Hopkins career, he was an associate professor in the Department of Oncology and an assistant professor of medical oncology. Dr. Drake received a BS in electrical engineering and MS in biomedical engineering from Rutgers University. He received a doctorate at the National Jewish Center for Immunology and Respiratory Medicine at the University of Colorado Health Sciences Center, and later earned his medical degree from the University of Colorado.

Elizabeth Jaffee, MD,
Deputy Director Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
The Dana and Albert “Cubby” Broccoli professor of oncology
President-elect of the American Association for Cancer Research (2017-2018)
Co-chair of the Blue Ribbon Panel for the National Cancer Moonshot Initiative

Dr. Jaffee is a distinguished leader in preclinical and early clinical development of vaccines for breast and pancreatic cancers. At Johns Hopkins, Dr. Jaffee is the deputy director of the Sidney Kimmel Comprehensive Cancer Center; associate director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy; and co-director of the Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care. Dr. Jaffee is the leader of the Stand Up To Cancer (SU2C)-Lustgarten Foundation Dream Team: Transforming Pancreatic Cancer to a Treatable Disease and serves as chair of the National Cancer Advisory Board for the National Cancer Institute and Cancer Research Institute’s Scientific Advisory Council. She graduated magna cum laude from Brandeis University before receiving her medical degree from New York Medical College.

Kwok-Kin Wong, M.D., Ph.D .
Chief of Hematology and Medical Oncology, New York University Langone Health Center
Anne Murnick Cogan and David H. Cogan Professor of Oncology, Department of Medicine

A renowned leader in the development of mouse models of lung cancer, Dr. Wong has made tremendous contributions to the understanding of the origins of cancer and the molecular determinants of treatment responses. Following a distinguished career at Harvard Medical School and the Dana-Farber Cancer Institute, Dr. Wong is currently Professor of Medicine and a practicing clinical oncologist at NYU Langone Health Center. While at Dana-Farber, Dr. Wong fostered partnerships with the pharmaceutical industry that accelerated cancer drug discovery. He directed the pioneering Belfer Center for Applied Cancer Research, a research center dedicated to translating current oncology research into clinical trials. Dr. Wong earned his M.D. and Ph.D. in the Integrated Program in Cellular, Molecular, and Biophysical Studies at Columbia University College of Physicians and Surgeons. He was trained in internal medicine at Massachusetts General Hospital and in hematology-oncology at Dana-Farber. He is a recipient of the 2010 Team Science Award from the American Association of Cancer Research.